Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent

(2011) Svitlana P. Grekova et al.   CANCER BIOLOGY & THERAPY

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Interferons as potential adjuvants in prophylactic vaccines

(2010) Roberta Toporovski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Current Status of Adjuvant Therapy for Pancreatic Cancer

(2010) M. H. G. Katz et al.   ONCOLOGIST

Clinical Use of Interferon-γ

(2009) Catriona H.T. Miller et al.   Annals of the New York Academy of Sciences

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide

(2009) X. Q. Lun et al.   CLINICAL CANCER RESEARCH

Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV

(2009) A. L. Angelova et al.   CLINICAL CANCER RESEARCH

Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages

(2009) Dorothée Duluc et al.   INTERNATIONAL JOURNAL OF CANCER

Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model

(2009) Hirano   ONCOLOGY REPORTS

Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer

(2008) Martin Loos et al.   CANCER LETTERS